Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kera Sol is a preservative-free ophthalmic lubricant (artificial tear) formulation designed to manage ocular surface irritation and dryness. It is specifically utilized in the treatment of surgical temporary ocular discomfort syndrome (STODS), a condition characterized by transient dry eye symptoms and corneal surface instability following refractive surgeries such as Laser-Assisted In Situ Keratomileusis (LASIK). Kera Sol functions by supplementing the natural tear film, providing a protective and lubricating layer over the cornea and conjunctiva. This action helps to mitigate post-operative symptoms such as grittiness, burning, and foreign body sensation while supporting the healing of the corneal epithelium during the initial recovery phase.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kera Sol.